Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1229

—

58b9a4a5-c453-57d9-8cb8-e34bd1c54f9d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.509
  • CHOLESTEROL_HOMEOSTASIS+0.474
  • G2M_CHECKPOINT+0.416
  • MTORC1_SIGNALING+0.373
  • MYC_TARGETS_V2+0.370
  • MYC_TARGETS_V1+0.330
  • PANCREAS_BETA_CELLS+0.247
  • OXIDATIVE_PHOSPHORYLATION+0.244
  • MITOTIC_SPINDLE+0.212
  • GLYCOLYSIS+0.206

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.616
  • INTERFERON_GAMMA_RESPONSE-0.530
  • ALLOGRAFT_REJECTION-0.420
  • HEDGEHOG_SIGNALING-0.347
  • TGF_BETA_SIGNALING-0.296
  • COMPLEMENT-0.270
  • IL6_JAK_STAT3_SIGNALING-0.269
  • KRAS_SIGNALING_UP-0.218
  • APICAL_SURFACE-0.205
  • INFLAMMATORY_RESPONSE-0.179

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR4296106
lung-landscapes@6
—cohortSQ10.875
2MNG1011
mng-umap@100
——0.870
3TCGA-77-6845-01A-11R-1949-07
lung-landscapes@6
—cohortSQ20.868
4SRR8518158
breast-umap@18
—E0.840
5MNG1082
mng-umap@100
——0.839
6TCGA-77-7140-01A-41R-2045-07
lung-landscapes@6
—cohortSQ20.839
7TCGA-94-8035-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.837
8TCGA-DQ-7588-01A-11R-2081-07
head-neck@1
——0.830
9X7c81e3d9.c538.468a.8a2a.f34513bac230
lung-landscapes@6
—cohortA30.824
10MNG1063
mng-umap@100
——0.820

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.509Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.474Remibrutinib— uncovered
G2M_CHECKPOINT0.416Inavolisib— uncovered
MTORC1_SIGNALING0.373Inavolisib— uncovered
MYC_TARGETS_V20.370Idelalisib— uncovered
MYC_TARGETS_V10.330Inavolisib— uncovered
PANCREAS_BETA_CELLS0.247Cobimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.244Remibrutinib— uncovered
MITOTIC_SPINDLE0.212Inavolisib— uncovered
GLYCOLYSIS0.206Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.188Inavolisib— uncovered
BILE_ACID_METABOLISM0.183Inavolisib— uncovered
HYPOXIA0.162Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.146Idelalisib— uncovered
FATTY_ACID_METABOLISM0.138Inavolisib— uncovered
DNA_REPAIR0.093Idelalisib— uncovered
SPERMATOGENESIS0.082Inavolisib— uncovered
PEROXISOME0.073Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.072Idelalisib— uncovered
ADIPOGENESIS0.062Inavolisib— uncovered